SCHEMBL3625529

SCHEMBL3625529

C[CH]c1ccc2ccc3cccc4ccc1c2c34

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
HPGD P15428 5/20 0.54
HSD17B10 Q99714 4/20 0.54
CYP3A4 P08684 2/20 0.54
TSHR P16473 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CYP1A2 P05177 4/20 0.48
CYP1A1 P04798 1/20 0.48
CYP1B1 Q16678 1/20 0.48
GUSB P08236 7/20 0.47
ERBB2 P04626 1/20 0.45
FYN P06241 1/20 0.45
MAOA P21397 1/20 0.45
ACHE P22303 1/20 0.45
AHR P35869 1/20 0.45
THRB P10828 1/20 0.44
KDM4E B2RXH2 3/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618747 0.85 ALDH1A1 (0.43) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL8371939 0.83 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL8371940 0.83 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL16177228 0.79 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL5830296 0.79 ALDH1A1 (0.52) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL15480135 0.79 GUSB (0.53) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL64873 0.78 ALDH1A1 (0.48) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL1032488 0.78 ALDH1A1 (0.48) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL16807027 0.78 GUSB (0.51) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL52121 0.78 ALDH1A1 (0.48) ALDH1A1HPGDHSD17B10CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019163245-A1 QUINONE ANALYSIS METHOD AND ONLINE SFE-SFC SYSTEM FOR IMPLEMENTING SAID METHOD 株式会社島津製作所 2019-08-29 WO claimed
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-07-18 US disclosed
US-12024658-B2 Water-based hybrid pressure sensitive adhesive composition and method of producing the same DOW SILICONES CORPORATION (US) 2024-07-02 US disclosed
EP-4375280-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-29 EP disclosed
EP-4371984-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4371985-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-3771731-B1 A CURABLE HOTMELT SILICONE COMPOSITION, ENCAPSULANT, FILM AND OPTICAL SEMICONDUCTOR DEVICE DUPONT TORAY SPECIALTY MATERIALS KK (JP) 2024-04-17 EP disclosed
CN-117881673-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-12 CN disclosed
CN-115038757-B Curable elastomer composition and method for designing transducer device 陶氏东丽株式会社 2024-04-05 CN disclosed
CN-117836290-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-05 CN disclosed
US-20160289499-A1 Silicone Material, Curable Silicone Composition, And Optical Device DOW TORAY CO., LTD. (JP) 2016-10-06 US disclosed
EP-3076443-A1 SILICONE MATERIAL, CURABLE SILICONE COMPOSITION, AND OPTICAL DEVICE Dow Corning Toray Co., Ltd. (JP) 2016-10-05 EP disclosed
US-20150344735-A1 Curable Silicone Composition, Cured Product Thereof, And Optical Semiconductor Device DOW CORNING TORAY CO., LTD. (JP) 2015-12-03 US disclosed
WO-2014104388-A2 CURABLE SILICONE COMPOSITION, CURED PRODUCT THEREOF, AND OPTICAL SEMICONDUCTOR DEVICE DOW CORNING TORAY CO., LTD. (JP) 2014-07-03 WO disclosed
US-7812155-B2 Process for preparing an o-alkylated rapamycin derivative and o-alkylated rapamycin derivative TERUMO KABUSHIKI KAISHA (JP) 2010-10-12 US disclosed
EP-2090580-A1 PROCESS FOR PRODUCING O-ALKYLATED RAPAMYCIN DERIVATIVE, AND O-ALKYLATED RAPAMYCIN DERIVATIVE Terumo Kabushiki Kaisha (JP) 2009-08-19 EP disclosed
US-20080146796-A1 Process for preparing an o-alkylated rapamycin derivative and o-alkylated rapamycin derivative TERUMO KABUSHIKI KAISHA (JP) 2008-06-19 US disclosed
US-20070263046-A1 Detection apparatus using cartridge SEKISUI CHEMICAL CO., LTD. (JP) 2007-11-15 US disclosed
EP-1852703-A1 DETECTION DEVICE USING CARTRIDGE SEKISUI CHEMICAL CO., LTD. (JP) 2007-11-07 EP disclosed
US-6303760-B1 TRIMETALLIC NITRIDE ENDOHEDRAL METALLOFULLERENES VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2001-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146796-A1 Process for preparing an o-alkylated rapamycin derivative and o-alkylated rapamycin derivative RICTOR, RPTOR, MTOR ALDH1A1 4261/4885HPGD 3466/4885HSD17B10 1295/4885
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN CYP7A1, UGT1A3, UGT1A1 ALDH1A1 225/4885HPGD 596/4885HSD17B10 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.